Wolfe Research Issues Negative Estimate for Biogen Earnings

Key Points

• Wolfe Research has lowered its Q4 2025 earnings estimate for Biogen to $3.27 per share, down from a previous estimate of $3.57.
• Multiple analysts have reduced Biogen's price targets, with Mizuho setting a target of $169.00 and Robert W. Baird setting a target of $255.00, both maintaining an "outperform" rating.
• Biogen's stock has experienced significant institutional interest, with 87.93% of shares currently owned by institutional investors and hedge funds.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities researchers at Wolfe Research cut their Q4 2025 earnings estimates for Biogen in a report released on Wednesday, August 6th. Wolfe Research analyst A. Hammond now expects that the biotechnology company will post earnings per share of $3.27 for the quarter, down from their previous forecast of $3.57. The consensus estimate for Biogen's current full-year earnings is $15.83 per share.

Several other research firms also recently commented on BIIB. Mizuho lowered their price objective on shares of Biogen from $207.00 to $169.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Robert W. Baird decreased their target price on shares of Biogen from $300.00 to $255.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Piper Sandler restated a "neutral" rating and set a $115.00 target price on shares of Biogen in a research report on Thursday, June 12th. The Goldman Sachs Group decreased their target price on shares of Biogen from $219.00 to $197.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, Oppenheimer set a $205.00 target price on shares of Biogen in a research report on Friday, May 2nd. Twenty-one equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $185.63.

Biogen Trading Up 2.3%

NASDAQ:BIIB opened at $130.67 on Monday. Biogen has a 12 month low of $110.04 and a 12 month high of $207.59. The firm has a fifty day simple moving average of $129.99 and a 200-day simple moving average of $131.30. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $19.16 billion, a P/E ratio of 12.49, a PEG ratio of 1.03 and a beta of 0.13.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, topping the consensus estimate of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same period in the previous year, the firm posted $5.28 earnings per share. The business's revenue for the quarter was up 7.3% compared to the same quarter last year.

Insiders Place Their Bets

In related news, insider Rachid Izzar sold 2,223 shares of the business's stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total transaction of $300,105.00. Following the transaction, the insider directly owned 6,330 shares in the company, valued at approximately $854,550. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.18% of the company's stock.

Hedge Funds Weigh In On Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Colonial Trust Co SC boosted its holdings in Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 186 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in Biogen in the 1st quarter valued at about $26,000. Greykasell Wealth Strategies Inc. acquired a new position in Biogen in the 1st quarter valued at about $27,000. Vision Financial Markets LLC acquired a new position in Biogen in the 1st quarter valued at about $27,000. Finally, Zions Bancorporation National Association UT acquired a new position in Biogen in the 1st quarter valued at about $29,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.